Impact of birth cohort screening for hepatitis C

Current Gastroenterology Reports

Volumn 16, Issue 4, 2014, Pages

  Asrani, Sumeet K ^a   Davis, Gary L ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b MedLogician Consulting   (United States)

Author keywords

Birth cohort; Burden; Incidence; Mortality; Prevalence

Indexed keywords

ARTICLE; BIRTH COHORT SCREENING; COST EFFECTIVENESS ANALYSIS; HEPATITIS C; HUMAN; INFECTION RISK; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; UNITED STATES; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; FORECASTING; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; MASS SCREENING; METHODOLOGY; PATIENT ATTITUDE; PRACTICE GUIDELINE;

ATTITUDE OF HEALTH PERSONNEL; COHORT STUDIES; COST-BENEFIT ANALYSIS; FORECASTING; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; UNITED STATES;

EID: 84894609186     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0381-5     Document Type: Article

References (31)

1. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1-32. CDC guideline for birth cohort screening.
2. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:101-8. USPSTF guideline for birth cohort screening with subsequent change from grade C to grade B recommendation.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42.
4. Anonymous. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 2000;75:18-19.
5. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62.
6. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82.
7. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14.
8. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859-61.
9. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55:1652-61.
10. Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology. 2001;34:1200-5.
11. Chung MY, Jun DW, Sung SA. Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis. Korean J Hepatol. 2010;16:301-7.
12. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-83.
13. Bornschlegel K, Holtzman D, Monina Klevens R, Ward JW. Vital signs: evaluation of hepatitis C virus infection testing and reporting - Eight U.S. Sites, 2005-2011. Morb Mortal Wkly Rep. 2013;62:357-61.
14. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182-8 e1181. Highlights change in epidemiology of HCV and its complications.
15. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl. 2012;18:1471-8.
16. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375-82.
17. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-8.
18. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-21, 521 e511-516. Markov modeling highlighting anticipated burden of liver disease.
19. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013;158:114-23.
20. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:509-16. e501.
21. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93.
22. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat. 2013. doi: 10.1111/jvh.12185
23. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329-37.
24. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-70.
25. McEwan P, Ward T, Yuan Y, Kim R, L'Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology. 2013;58:54-64.
26. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55:1344-55.
27. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat. 2013;20:550-5.
28. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol. 2013;108:981-9.
29. Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172:575-82.
30. Galbraith JW, Franco R, Rodgers JB. Screening in emergency department identifies a large cohort of unrecognized chronic hepatitis C virus infection among baby boomers. Hepatology. 2013;58:LB6.
31. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006;43:S113-20.